Researchers at Yale School of Medicine have discovered that as brain cancers become more resistant to treatment, they develop a variety of mutations that differ from one type of brain cancer to another. The findings, published in a recent study, could pave the way for more targeted treatments and allow clinicians to move away from one-size-fits-all approaches toward personalized therapies.
The team focused on oligodendrogliomas and astrocytomas, common types of gliomas that afflict humans. They found that as these sub-categories of brain cancer become more aggressive, they develop mutations that are radically different. For a long time, scientists have worked based on the thinking that these cancers recur because surgery and other forms of treatment are unable to remove or kill all the cancerous tissues. The residual tissues therefore regrow, but it has not been clear why the subsequent tumors are more aggressive.
The Yale researchers sought to get insights into the biological mechanisms underpinning the aggressive gliomas that resist treatment. For their study, the team obtained paired brain cancer tissue samples from each of approximately 180 patients from around the world. The first sample was taken at the time when the brain cancer had just been diagnosed while the second was extracted when the cancer recurred. They then analyzed the DNA of the samples and compared the before and after cancer recurrence mutations. They found that the two sets had mutations that differed radically, and those differences tended to be specific to the subtype of glioma.
Astrocytomas developed DNA copy-number changes involving deletions or extra copies of entire genome sections, while oligodendrogliomas developed many single-point mutations in cancer genes. While both kinds of cancer looked similar when examined from the point of their phenotype, they markedly differed when compared from the perspective of their DNA. This suggests that treatment approaches should focus more on the DNA of the cancers instead of targeting the phenotype while selecting treatment options. In this way, treatment resistance could be avoided if patients are monitored for DNA mutations and the treatment is adjusted proactively to address those DNA changes observed.
The big question that the researchers have for the scientific community is whether those mutations can be predicted and acted upon before they happen so that brain cancer patients can survive for a lot longer than they currently do. That is a big question that cancer therapy developers like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are likely to ponder as they conduct their R&D programs geared at transforming the way cancers affecting the brain are treated. This challenge adds to existing cancer therapy hurdles, such as how to get past the blood-brain barrier that prevents most treatments from reaching the brain.
The implications of this research are significant for patients, clinicians, and the biotechnology industry. If DNA mutations driving resistance can be identified early, oncologists could switch therapies before tumors become fully resistant, potentially extending survival. For drug developers, the findings highlight the need to design treatments that target specific genetic alterations rather than broad phenotypic features. As the research community grapples with these questions, platforms like BioMedWire continue to report on developments in the biotechnology, biomedical sciences, and life sciences sectors, which are part of the Dynamic Brand Portfolio at IBN. The study underscores the growing emphasis on personalized medicine in neuro-oncology and the urgent need for innovative strategies to overcome treatment resistance in brain cancers.
